Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.
2.

Enhanced production of Chikungunya virus-like particles using a high-pH adapted spodoptera frugiperda insect cell line.

Wagner JM, Pajerowski JD, Daniels CL, McHugh PM, Flynn JA, Balliet JW, Casimiro DR, Subramanian S.

PLoS One. 2014 Apr 8;9(4):e94401. doi: 10.1371/journal.pone.0094401. eCollection 2014.

3.

Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs.

Awasthi S, Balliet JW, Flynn JA, Lubinski JM, Shaw CE, DiStefano DJ, Cai M, Brown M, Smith JF, Kowalski R, Swoyer R, Galli J, Copeland V, Rios S, Davidson RC, Salnikova M, Kingsley S, Bryan J, Casimiro DR, Friedman HM.

J Virol. 2014 Feb;88(4):2000-10. doi: 10.1128/JVI.03163-13. Epub 2013 Nov 27.

4.

Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread.

Awasthi S, Zumbrun EE, Si H, Wang F, Shaw CE, Cai M, Lubinski JM, Barrett SM, Balliet JW, Flynn JA, Casimiro DR, Bryan JT, Friedman HM.

J Virol. 2012 Apr;86(8):4586-98. doi: 10.1128/JVI.07203-11. Epub 2012 Feb 8.

5.

Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone.

Awasthi S, Lubinski JM, Shaw CE, Barrett SM, Cai M, Wang F, Betts M, Kingsley S, Distefano DJ, Balliet JW, Flynn JA, Casimiro DR, Bryan JT, Friedman HM.

J Virol. 2011 Oct;85(20):10472-86. doi: 10.1128/JVI.00849-11. Epub 2011 Aug 3.

7.

ICP22 is required for wild-type composition and infectivity of herpes simplex virus type 1 virions.

Orlando JS, Balliet JW, Kushnir AS, Astor TL, Kosz-Vnenchak M, Rice SA, Knipe DM, Schaffer PA.

J Virol. 2006 Oct;80(19):9381-90.

8.

ICP0 antagonizes Stat 1-dependent repression of herpes simplex virus: implications for the regulation of viral latency.

Halford WP, Weisend C, Grace J, Soboleski M, Carr DJ, Balliet JW, Imai Y, Margolis TP, Gebhardt BM.

Virol J. 2006 Jun 9;3:44.

11.

Heptad repeat 2-based peptides inhibit avian sarcoma and leukosis virus subgroup a infection and identify a fusion intermediate.

Netter RC, Amberg SM, Balliet JW, Biscone MJ, Vermeulen A, Earp LJ, White JM, Bates P.

J Virol. 2004 Dec;78(24):13430-9.

12.

Re-evaluating natural resistance to herpes simplex virus type 1.

Halford WP, Balliet JW, Gebhardt BM.

J Virol. 2004 Sep;78(18):10086-95.

13.
14.

Production and characterization of a soluble, active form of Tva, the subgroup A avian sarcoma and leukosis virus receptor.

Balliet JW, Berson J, D'Cruz CM, Huang J, Crane J, Gilbert JM, Bates P.

J Virol. 1999 Apr;73(4):3054-61.

15.
16.

Receptor-induced conformational changes in the subgroup A avian leukosis and sarcoma virus envelope glycoprotein.

Gilbert JM, Hernandez LD, Balliet JW, Bates P, White JM.

J Virol. 1995 Dec;69(12):7410-5.

17.

V3-independent determinants of macrophage tropism in a primary human immunodeficiency virus type 1 isolate.

Kim FM, Kolson DL, Balliet JW, Srinivasan A, Collman RG.

J Virol. 1995 Mar;69(3):1755-61.

18.

Human immunodeficiency virus type 1 Tat activity in human neuronal cells: uptake and trans-activation.

Kolson DL, Collman R, Hrin R, Balliet JW, Laughlin M, McGann KA, Debouck C, Gonzalez-Scarano F.

J Gen Virol. 1994 Aug;75 ( Pt 8):1927-34.

PMID:
8046394
19.
20.

An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1.

Collman R, Balliet JW, Gregory SA, Friedman H, Kolson DL, Nathanson N, Srinivasan A.

J Virol. 1992 Dec;66(12):7517-21.

Supplemental Content

Loading ...
Support Center